ADIAL PHARMACEUTICALS, INC. (ADIL) Stock Price, Financials & Summary

Price chart

Oct 1Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30

Key dataOct 30, 2026

Open$4.71

From 52W high−43.89%

Volume169247.00

Market cap$13.26M

P/E (TTM)—

P/S (TTM)—

Div yield—

Key dataOct 30, 2026

Open

$4.71

From 52W high

−43.89%

Volume

169247.00

Market cap

$13.26M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−0.4x

P/E (TTM)

—

RSI (14)

46.5

MomentumView details →

1D Return

+36.12%

YTD Return

−30.73%

SummaryUpdated Jun 1, 2026

Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) is a clinical-stage biopharmaceutical company founded in 2010 and headquartered in Charlottesville, Virginia. The company went public in July 2018 and focuses on developing therapeutic treatments for addiction and related disorders. Adial is currently advancing its lead drug candidate through late-stage clinical trials, representing a specialized approach to addressing substance use disorders through targeted pharmaceutical interventions.

Ask drillr about ADIAL PHARMACEUTICALS, INC. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−0.4x

EV/Sales

—

P/S (TTM)

—

P/B (TTM)

85.0x

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

—

ROA (TTM)

−198.70%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

—

EPS YoY

+34.53%

FCF YoY

−71.74%

Revenue CAGR 3Y

—

EPS CAGR 3Y

+32.79%

EBITDA YoY

—

MomentumView details →

1D Return

+36.12%

YTD Return

−30.73%

1Y Return

−56.46%

RSI (14)

46.5

vs 50D SMA

−18.74%

vs 200D SMA

+18.13%

Capital & dividendView details →

Debt/Equity

0.00x

Current Ratio

5.63x

Quick Ratio

5.63x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$11.25

EPS Surprise

−992.23%

Beats (12Q)

8/12

Next Q EPS Est

—

Avg Surprise (4Q)

−252.85%

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

−57.80M

Op. CF (TTM)

−11.13M

Latest newsMore news →

Adial Pharmaceuticals appointed Julie Saiki as chief strategy officer, effective October 28, 2026.7d ago

Adial Pharmaceuticals appointed Matthew Davidson as president and chief executive officer, replacing Cary J. Claiborne, effective October 28, 2026.7d ago

Similar companies

Cuprina Holdings (Cayman) Limited Class A Ordinary SharesCUPR Daré Bioscience, Inc.DARE TScan Therapeutics, Inc.TCRX Radiopharm Theranostics LimitedRADX Fractyl Health, Inc. Common StockGUTS Vyome Holdings, Inc.HIND Find similar companies →

Latest newsMore news →

Adial Pharmaceuticals appointed Julie Saiki as chief strategy officer, effective October 28, 2026.7d ago Adial Pharmaceuticals appointed Matthew Davidson as president and chief executive officer, replacing Cary J. Claiborne, effective October 28, 2026.7d ago